Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Outlook Therapeutics, Inc.
Age
50–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Active primary Subfoveal Choroidal Neovascularization lesions secondary to Age-related macular degeneration (AMD) in the study eye
Best corrected visual acuity of 25-67 letters read (20/50 to 20/320 Snellen equivalent)
Study eye must:
* Have active leakage on Fluorescein Angiogram involving the fovea
* Have edema involving the fovea
* Be free of scarring, fibrosis, or atrophy involving the central foveal zone
You may not be if
Previous subfoveal focal laser photocoagulation in the study eye
Laser photocoagulation (juxtafoveal or extrafoveal) in the study eye within 1-month preceding randomization
Any concurrent intraocular condition in the study eye that may require medical or surgical intervention or contribute to vision loss within 1 year
Active intraocular inflammation (grade trace or above) in the study eye
Current vitreous haemorrhage in the study eye
Polypoidal choroidal vasculopathy (PCV) in the study eye
History of idiopathic or autoimmune-associated uveitis in either eye
Infectious conjunctivitis, keratitis, scleritis, or endophthalmitis in either eye
Uncontrolled glaucoma in the study eye (defined as intraocular pressure ≥30 mmHg despite treatment with anti-glaucoma medication)
Premenopausal women not using adequate contraception
Current treatment for active systemic infection
Known allergy to any component of the study drug or history of allergy to fluorescein , not amenable to treatment
Clareo Health | A Clinical Effectiveness Study Examining the Efficacy and Safety of ONS-5010 in Subjects With Neovascular Age-related Macular Degeneration (AMD)
